



An International
Center of Reference
for Translational
Oncology Research



Vall d'Hebron
Hospital

VHIO ^R

VALL D'HEBRON
Institute of Oncology





**Dr. José Baselga,
Director &
Head of Research.**

**“Cancer is one of the top
health issues with a rising trend
in first-world countries”**

José Baselga is Director of the Vall d’Hebron Institute of Oncology (VHIO), Chairman of the Medical Oncology Service and Director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d’Hebron University Hospital in Barcelona, Spain. He is also President of the Spanish Breast Cancer Cooperative Group, SOLTI and serves as Member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, Clinical Cancer Research and Annuals of Oncology. He has published over 200 peer-reviewed articles and over 300 abstracts and book chapters.

He sits on several Committees of the American Association for Cancer Research (AACR) and is a Member of the AACR Research Council and Member of ECCO, the European Cancer Organisation’s Executive Committee. He is a former Member of the Board of Directors of the American Society of Clinical Oncology (ASCO), a former member of the board of directors of the European Organization of Research on Treatment of Cancer (EORTC) and a Member of the Scientific Advisory Committee of the Ludwig Institute for Cancer Research. He is immediate Past President of the European Society of Medical Oncology (ESMO).

AWARDS AND PRIZES:

AACR-Rosenthal Family Foundation Award, 2008

Jaume I Award, 2008

Prize for Scientific Excellence in Medicine, 2007

Bristol-Myers Squibb Unrestricted Cancer Grant Award, 2002-2006

Annual Award from ESMO, 2005

Distinguished Alumnus from Memorial Sloan Kettering Cancer Center, NY, 2004

Elected Member of the American Society of Clinical Investigation, 2004

Honorary Membership Award from the European Society for Therapeutic Radiology and Oncology (ESTRO), 2004


Anderson Cancer Center in Houston, TX, 2002

Career Development Award from ASCO, 1994

Young Investigator Award from ASCO, 1992

American- Italian Cancer Foundation (AICF)

Waun Ki Hong Visiting Professorship at U.T.M.D.



About VHIO

The Vall d'Hebron Institute of Oncology (VHIO) was established in late 2006, as a non-profit foundation, located at the Vall d'Hebron University Hospital (VHUH). It strives to respond to the challenges at the forefront of oncological research.

THE VHIO MISSION

- To promote the development of scientific research into pioneering clinical practice, and thus enable our patients to benefit from the very latest advances in oncological research
- To carry out scientific research of excellence in all areas, with specific emphasis on basic, translational and clinical research
- To foster scientific cooperation and collaboration among national and international cancer research centers
- To promote all cancer research aimed at improving the quality of life for cancer patients.



The Hospital

Vall d'Hebron University Hospital (VHUH) is the largest hospital in Barcelona and the second largest in Spain, spanning almost all medical and surgical specialities. It has more than 1400 beds, employs over 6000 people and houses various teaching centers, a medical school, public health facilities, research centers, laboratories and other complementary facilities.

This environment provides VHIO with one of the best health care platforms for carrying out oncological research including:

- An excellent clinical environment for the treatment of cancer diseases.
- Multidisciplinary facilities.
- University health care teams specializing in clinical and translational research.
- Basic research equipment and laboratories.
- Technological platforms, including Pathological Anatomy, Genomics, Proteomics and Molecular Imaging.



Translational Research

The main focus of research over recent years has been on the development of molecularly targeted agents and the identification of biomarkers that predict sensitivity or resistance to these agents.

VHIO has been involved in the clinical development of several new agents including gefitinib, erlotinib, lapatinib, pertuzumab, m-TOR inhibitors, PI3K inhibitors, TGF β inhibitors, SRC inhibitors, insulin-like growth factor receptor inhibitors and a variety of antiangiogenic agents. Many of these agents are now approved anti-cancer therapeutic agents.

VHIO strives to become one of the world's leading oncological institutes, by placing innovative clinical research at center of its activities, and connecting basic research with translational science.

Researchers have exceptional access to a large body of patient groups, clinical samples, and state-of-the-art health care technology, all of which sets VHIO aside from other research centers.

The scientific structure of VHIO is similar to that of other leading international research centers.

VHIO has several research lines, each led by a Principal Investigator (PI) - ranging from basic to clinical research, and all share a fundamental, collective confidence in the value of translational research.



The Team

BASIC RESEARCH TEAMS:

- Animal Models Laboratory. PI Juan A. Recio
- Gene Expression and Cancer Laboratory.
PI Joan Seoane (ICREA Research Professor)
- Growth Factors Laboratory.
PI Joaquín Arribas (ICREA Research Professor)
- Proteomics Laboratory. PI Francesc Canals
- Targeted Cancer Proteomics Laboratory.
PI Josep Villanueva
- Stem Cells and Cancer Laboratory.
PI Héctor García-Palmer

CLINICAL RESEARCH:

- Breast Cancer Program. PI Javier Cortés
- Experimental Therapies Program.
PI José Baselga
- Gastrointestinal Tumors Program.
PI Josep Tabernero
- Genitourinary Tumors Program. PI Joan Carles
- Head, Neck and Gynecological Tumors Program.
PI Josep M. del Campo
- High Risk and Cancer Prevention Program.
PI Judith Balmaña and Orland Díez
- Lung Cancer Program. PI Enriqueta Felip
- Molecular Pathology Program.
PI Santiago Ramon y Cajal
- Radiation Oncology Program. PI Jordi Giralt



New Projects

CELLEX Building

Committed to the support of science, the Cellex Private Foundation provides VHIO with a state-of-the-art Oncology Research Building. The Cellex Building will host both basic and clinical researchers and it will bring together investigators who are currently working in different VHUH buildings.

“la Caixa” CANCER MOLECULAR THERAPY UNIT

Obra Social “la Caixa”, a Member of the VHIO Foundation, has supported the creation and set up of the Cancer Molecular Therapy Unit—Molecular Therapy Research Unit—to research new molecular targets and new pharmacological agents aimed at these targets. It has also sponsored the corresponding pharmacokinetics laboratory.

The objective of this unit is to carry out experimental studies with new drugs and therapeutic targets. The phase I clinical trials include studies carried out in human beings aimed at demonstrating the safety of the compounds and ascertaining the most appropriate dosage.

The Molecular Therapy Unit will carry out clinical pharmacology and toxicity studies. The facilities will be housed by the 900 m² on the ground floor of the VHUH general area building.



Sources of Funding


VHIO benefits from both public and private funding. Public funding comes from the Catalan Ministry of Health (Departament de Salut) and the Catalan Ministry of Universities, Innovation and Enterprise (Departament d'Universitats, Innovació i Empresa), both belonging to the Catalan Regional Government (Generalitat de Catalunya).

Private investment is a crucial source of VHIO funding, by means of both competitive support and philanthropic donations.



FUNDACION
CELLEX





Contact us

VALL D'HEBRON INSTITUTE OF ONCOLOGY

Passeig Vall d'Hebron 119-129
Edificio Maternoinfantil, planta 14
08035 Barcelona
(+34) 93 489 30 21
info@vhio.net
www.vhio.net